Laboratory Corporation of America Holdings which can be found using ticker (LH) have now 14 market analysts covering the stock. The analyst consensus now points to a rating of ‘buy’. The range between the high target price and low target price is between 290 and 215 with the average target price sitting at $255.07. Now with the previous closing price of $215.26 and the analysts are correct then we can expect a percentage increase in value of 18.5%. Also worth taking note is the 50 day moving average now sits at $203.59 while the 200 day moving average is $201.29. The total market capitalization for the company now stands at 19.07B. The stock price for the company is currently is currently 215.23 USD
The potential market cap would be $22,596,053,095 based on the market consensus.
The company is not paying dividends at this time.
Other points of data to note are a P/E ratio of 19.34, revenue per share of 167.11 and a 5.51% return on assets.
Laboratory Corporation of America Holdings is a global life sciences company. The Company provides information to help doctors, hospitals, pharmaceutical companies, researchers, and patients make decisions. The Company’s segments include Labcorp Diagnostics (Dx) and Labcorp Drug Development (DD). The Dx segment is an independent clinical laboratory business. It offers a menu of frequently requested and specialty diagnostic tests through an integrated network of primary and specialty laboratories across the United States. In addition to diagnostic testing along with occupational and wellness testing for employers and forensic DNA analysis, Dx segment also offers a range of other testing services. The DD segment is a contract research organizations business that provides end-to-end drug development services. The DD segment provides these services predominantly to pharmaceutical, biotechnology and medical device companies across the world. It serves clients in more than 100 countries.
